此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers

2014年10月28日 更新者:Boehringer Ingelheim

A Single Increasing Dose Safety, Tolerability and Pharmacodynamics (Methacholine Challenge) Study After Inhalational Administration of BIIX 1 XX (Single Doses: 5 - 800 mcg) in Healthy Young Male Volunteers (Randomised, Double-blind, Placebo-controlled)

The objective of the present study is to obtain information about the safety and tolerability of BIIX 1 XX, to determine the pharmacologically active dose (range) by performing a methacholine challenge test and to obtain preliminary pharmacokinetic data

研究概览

地位

完全的

条件

干预/治疗

研究类型

介入性

注册 (实际的)

24

阶段

  • 阶段1

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Healthy male volunteers who have Broca-Indices within +-20%
  • Participants in the age range between 21 to 50 years
  • Following the methacholine challenge the airway resistance (Raw) shows an increase of at least 130%
  • In accordance with Good Clinical Practice (GCP) and local legislation each volunteer is supposed to give his written informed consent prior to admission to the study
  • As part of the screening (within 14 days before drug administration), each subject was to receive a complete medical examination (including blood pressure, pulse rate, medical history, documentation of demographics, inclusion/exclusion criteria and concomitant therapy) as well as a 12-lead Electrocardiogram (ECG)
  • Haematopoietic, hepatic and renal function test will be carried out in the laboratory
  • The subjects will fast for 12 hours before collection of specimens for all laboratory evaluations. The above mentioned examinations will be performed within 14 days before the first administration of the test substance

Exclusion Criteria:

  • Volunteers will be excluded from the study if the results of the medical examination or laboratory tests are judged by the clinical investigator to differ significantly from normal clinical values
  • Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Volunteers with diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of a drug with a long half-life (>= 24 hours) within one month before enrolment in the study
  • Use of any drugs which might influence the results of the trial the week previous to the start of the study
  • Participation in another study with an investigational drug within the last two months preceding this study
  • Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
  • Inability to refrain from smoking on study days
  • Alcohol abuse (> 60g/day)
  • Drug abuse
  • Blood donation within the last 4 weeks
  • Excessive physical activities within the last week before the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:单组作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂
实验性的:BIIX 1 XX - single rising dose

研究衡量的是什么?

主要结果指标

结果测量
大体时间
实验室参数异常变化的受试者人数
大体时间:最后一次给药后最多 8 天
最后一次给药后最多 8 天
Number of subjects with adverse events
大体时间:up to 3 months
up to 3 months
Change in impedance cardiography
大体时间:up to 30 minutes after drug administration
up to 30 minutes after drug administration
Change in cutaneous microcirculation
大体时间:up to 30 minutes after drug administration
up to 30 minutes after drug administration

次要结果测量

结果测量
大体时间
Change in airway resistance (Raw) after methacholine challenge
大体时间:up to 30 minutes after drug administration
up to 30 minutes after drug administration
Change in specific conductance (sGaw) after methacholine challenge
大体时间:up to 30 minutes after drug administration
up to 30 minutes after drug administration
AUC (Area under the concentration-time curve of the analyte in plasma)
大体时间:up to 168 hours after drug administration
up to 168 hours after drug administration
Cmax (Maximum measured concentration of the analyte in plasma)
大体时间:up to 168 hours after drug administration
up to 168 hours after drug administration
tmax (Time from dosing to the maximum concentration of the analyte in plasma)
大体时间:up to 168 hours after drug administration
up to 168 hours after drug administration
Ae (Amount of analyte that is eliminated in urine)
大体时间:up to 48 hours after drug administration
up to 48 hours after drug administration
MRT (Mean residence time of the analyte in the body)
大体时间:up to 168 hours after drug administration
up to 168 hours after drug administration
t½ (Terminal half-life of the analyte in plasma)
大体时间:up to 168 hours after drug administration
up to 168 hours after drug administration
CL/F(Apparent clearance of the analyte in plasma following extravascular administration)
大体时间:up to 168 hours after drug administration
up to 168 hours after drug administration

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

1998年6月1日

初级完成 (实际的)

1998年9月1日

研究注册日期

首次提交

2014年7月24日

首先提交符合 QC 标准的

2014年7月24日

首次发布 (估计)

2014年7月25日

研究记录更新

最后更新发布 (估计)

2014年10月29日

上次提交的符合 QC 标准的更新

2014年10月28日

最后验证

2014年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • 1150.1

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.